Erythropoietin Stimulating Agents Market: Global Industry Size, Outlook, Growth and Forecast to 2022 by Brisk Insights

Friar Lane, United Kingdom, June 26, 2016 --(PR.com)-- According to a recently published report, the global Erythropoietin Stimulating Agents Market is expected to grow $7.4billion by 2022with the CAGR of 0.3% during 2015-2022. The segmentation of global erythropoietin stimulating agents market is based on products, application, and Region. The report on global erythropoietin stimulating agents market forecast 2015-2022 (products, application and region) provides a detailed overview and predictive analysis of the market.

The erythropoietin is a glycoprotein hormone synthesized in the bone marrow that controls and regulates the mechanism of erythropoiesis. These EPO drugs are used for treatment of chemotherapy induced anemia. The global EPO agents market is thus driven by increasing number of patients suffering from anemic condition induced due to cancer, HIV, and kidney failures. The cancer, HIV, kidney diseases are very chronic diseases and are responsible for large number of deaths worldwide. Over 80% of the population in the world is dying from chronic diseases, 13 million are died in 2014 from cancer, more than 7.3 million are suffering from HIV, more than 4.7 million are suffering from kidney diseases and this facts is expected to rise in near future, these types of diseases cause anemia or lack of red blood cells in human body. An erythropoiesis stimulating agent or drug is a medicine which stimulates red blood cells protein erythropoiesis. They are used in conditions where reduced blood cells production causes anemia. The global erythropoietin stimulating agents market is driving with the rising number of anemia cases in the world. Increasing awareness of EOP therapies in the treatment of anemia also pushes the market upwards.

Detailed study on this Report: http://www.briskinsights.com/report/erythropoietin-stimulating-agents-market